ATLASATLAS fair value
ATLAS has no fair value for this stock today.
UroGen Pharma (URGN)
UroGen Pharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$33.91▼ -0.38%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on UroGen Pharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On UroGen Pharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives UroGen Pharma a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $30.85 and $36.88; in 9 out of 10, between $26.34 and $43.20. Estimated annual volatility is 46%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.8B
- 52-week high
- $50.81
- 52-week low
- $16.50
- Revenue (12 months)
- $189M
- Revenue growth (YoY)
- +21.5%
- Gross margin
- 88.7%
- Operating margin
- -113.7%
- Net margin
- -139.8%
- Return on equity
- 145.5%
- Free cash flow (12 months)
- $-107M
- Beta
- 1.58
What this means
ATLAS does not publish a fair value for URGN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks URGN has traded between $16.50 and $50.81. Today it is 33.3% below that high and 106% above its low.
On the business: revenue grew 21.5% year over year; net margin is 139.8%.
Its beta is 1.58: it tends to move more than the market, both up and down.
About the company
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers.
Want to see everything about UroGen Pharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does UroGen Pharma do?
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers.
What is the chance URGN goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, URGN ends the month between $30.85 and $36.88.
How big is UroGen Pharma and what is its P/E ratio?
UroGen Pharma's market capitalization is $1.8B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is URGN?
ATLAS estimates annual volatility at 46%. In a typical month, half of the outcomes end between $30.85 and $36.88.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer